Reviewing Sunny Optical Technology (Group) (OTCMKTS:SNPTF) & Evolus (NASDAQ:EOLS)

Sunny Optical Technology (Group) (OTCMKTS:SNPTF) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Institutional & Insider Ownership

90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sunny Optical Technology (Group) and Evolus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunny Optical Technology (Group)	0	0	0	0	0.00
Evolus	1	1	4	0	2.50

Evolus has a consensus target price of $16.00, indicating a potential upside of 145.78%. Given Evolus’ stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Sunny Optical Technology (Group).

Profitability

This table compares Sunny Optical Technology (Group) and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunny Optical Technology (Group)	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

Volatility & Risk

Sunny Optical Technology (Group) has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares Sunny Optical Technology (Group) and Evolus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunny Optical Technology (Group)	$5.33 billion	1.97	$375.45 million	N/A	N/A
Evolus	$297.18 million	1.44	-$51.64 million	($0.67)	-9.72

Sunny Optical Technology (Group) has higher revenue and earnings than Evolus.

Summary

Evolus beats Sunny Optical Technology (Group) on 6 of the 11 factors compared between the two stocks.

About Sunny Optical Technology (Group)

Sunny Optical Technology (Group) Company Limited, an investment holding company, engages in designing, researching, developing, manufacturing, and selling optical and optical related products, and scientific instruments. The company's Optical Components segment offers glass spherical and aspherical lenses, handset lens sets, vehicle lens sets, security surveillance lens sets, and other lens sets. Its Optoelectronic Products segment comprise handset camera modules, three dimensional optoelectronic products, vehicle modules, and other optoelectronic modules. The company's Optical Instruments segment includes microscopes and intelligent inspection equipment for testing. Its optoelectronic-related products are used in handsets, digital cameras, vehicle imaging and sensing systems, security surveillance systems, virtual reality/augmented reality, and robots, which are combined with optical, electronic, algorithm, and mechanical technologies. In addition, the company engages in the research and development of infrared and semiconductor technologies; trading of optical instruments and optoelectronics products; property leasing activities; and development, service, and consultation of technology; provision of financing services; and import and export agency services. It operates primarily in the People's Republic of China, rest of Asia, Europe, North America, and internationally. The company was founded in 1984 and is headquartered in Yuyao, China.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.